On 15 September 2026, The Economic Times reported that Dr Reddy’s has launched Nivorz™, biosimilar to BMS’ Opdivo® (nivolumab), in India. Nivorz™ will be available in single-dose vial presentations (40 mg, 100 mg and 240 mg) and will be manufactured at Dr Reddy’s biologics facility in Bachupally, Hyderabad.
Nivorz™ is the second nivolumab biosimilar to be launched in India following Zydus’ Tishtha®, which was the first nivolumab biosimilar to be launched in the world when it became available in India in January 2026 (approved July 2024).
Multiple nivolumab biosimilars are under development including Sandoz’s JPB898, Xbrane/Intas’ Xdivane™, Amgen’s ABP 206, Reliance Life Sciences’ RLS-Nivolumab, Enzene’s candidate, and Boan Biotech’s BA1104.